300 related articles for article (PubMed ID: 36421839)
1. Regulation of DNA Methylation by Cannabidiol and Its Implications for Psychiatry: New Insights from In Vivo and In Silico Models.
Domingos LB; Silva NR; Chaves Filho AJM; Sales AJ; Starnawska A; Joca S
Genes (Basel); 2022 Nov; 13(11):. PubMed ID: 36421839
[TBL] [Abstract][Full Text] [Related]
2. CBD modulates DNA methylation in the prefrontal cortex and hippocampus of mice exposed to forced swim.
Sales AJ; Guimarães FS; Joca SRL
Behav Brain Res; 2020 Jun; 388():112627. PubMed ID: 32348868
[TBL] [Abstract][Full Text] [Related]
3. Cannabidiol prevents disruptions in sensorimotor gating induced by psychotomimetic drugs that last for 24-h with probable involvement of epigenetic changes in the ventral striatum.
Pedrazzi JFC; Sales AJ; Guimarães FS; Joca SRL; Crippa JAS; Del Bel E
Prog Neuropsychopharmacol Biol Psychiatry; 2021 Dec; 111():110352. PubMed ID: 34015384
[TBL] [Abstract][Full Text] [Related]
4. Cannabidiol as a Potential Treatment for Anxiety and Mood Disorders: Molecular Targets and Epigenetic Insights from Preclinical Research.
Melas PA; Scherma M; Fratta W; Cifani C; Fadda P
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33668469
[TBL] [Abstract][Full Text] [Related]
5. Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders.
Campos AC; Moreira FA; Gomes FV; Del Bel EA; Guimarães FS
Philos Trans R Soc Lond B Biol Sci; 2012 Dec; 367(1607):3364-78. PubMed ID: 23108553
[TBL] [Abstract][Full Text] [Related]
6. Opposite Roles for Cannabidiol and δ-9-Tetrahydrocannabinol in Psychotomimetic Effects of Cannabis Extracts: A Naturalistic Controlled Study.
Sainz-Cort A; Jimenez-Garrido D; Muñoz-Marron E; Viejo-Sobera R; Heeroma J; Bouso JC
J Clin Psychopharmacol; 2021 Sep-Oct 01; 41(5):561-570. PubMed ID: 34412109
[TBL] [Abstract][Full Text] [Related]
7. The (Poly)Pharmacology of Cannabidiol in Neurological and Neuropsychiatric Disorders: Molecular Mechanisms and Targets.
Vitale RM; Iannotti FA; Amodeo P
Int J Mol Sci; 2021 May; 22(9):. PubMed ID: 34062987
[TBL] [Abstract][Full Text] [Related]
8. Translational Investigation of the Therapeutic Potential of Cannabidiol (CBD): Toward a New Age.
Crippa JA; Guimarães FS; Campos AC; Zuardi AW
Front Immunol; 2018; 9():2009. PubMed ID: 30298064
[No Abstract] [Full Text] [Related]
9. Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug.
Schier AR; Ribeiro NP; Silva AC; Hallak JE; Crippa JA; Nardi AE; Zuardi AW
Braz J Psychiatry; 2012 Jun; 34 Suppl 1():S104-10. PubMed ID: 22729452
[TBL] [Abstract][Full Text] [Related]
10. A scoping review of the use of cannabidiol in psychiatric disorders.
Kirkland AE; Fadus MC; Gruber SA; Gray KM; Wilens TE; Squeglia LM
Psychiatry Res; 2022 Feb; 308():114347. PubMed ID: 34952255
[TBL] [Abstract][Full Text] [Related]
11. Is there a role for cannabidiol in psychiatry?
Khoury JM; Neves MCLD; Roque MAV; Queiroz DAB; Corrêa de Freitas AA; de Fátima Â; Moreira FA; Garcia FD
World J Biol Psychiatry; 2019 Feb; 20(2):101-116. PubMed ID: 28112021
[TBL] [Abstract][Full Text] [Related]
12. Synthetic and Natural Derivatives of Cannabidiol.
Morales P; Jagerovic N
Adv Exp Med Biol; 2021; 1297():11-25. PubMed ID: 33537934
[TBL] [Abstract][Full Text] [Related]
13. Cannabidiol in medicine: a review of its therapeutic potential in CNS disorders.
Scuderi C; Filippis DD; Iuvone T; Blasio A; Steardo A; Esposito G
Phytother Res; 2009 May; 23(5):597-602. PubMed ID: 18844286
[TBL] [Abstract][Full Text] [Related]
14. Cannabidiol: Recent advances and new insights for neuropsychiatric disorders treatment.
Premoli M; Aria F; Bonini SA; Maccarinelli G; Gianoncelli A; Pina SD; Tambaro S; Memo M; Mastinu A
Life Sci; 2019 May; 224():120-127. PubMed ID: 30910646
[TBL] [Abstract][Full Text] [Related]
15. Cannabidiol, a Regulator of Intracellular Calcium and Calpain.
Jeon KH; Park SH; Bae WJ; Kim SW; Park HJ; Kim S; Kim TH; Jeon SH; Park I; Park HJ; Kwon Y
Cannabis Cannabinoid Res; 2023 Feb; 8(1):119-125. PubMed ID: 35196129
[TBL] [Abstract][Full Text] [Related]
16. Cannabidiol, neuroprotection and neuropsychiatric disorders.
Campos AC; Fogaça MV; Sonego AB; Guimarães FS
Pharmacol Res; 2016 Oct; 112():119-127. PubMed ID: 26845349
[TBL] [Abstract][Full Text] [Related]
17. Preclinical and Clinical Evidence Supporting Use of Cannabidiol in Psychiatry.
Calapai G; Mannucci C; Chinou I; Cardia L; Calapai F; Sorbara EE; Firenzuoli B; Ricca V; Gensini GF; Firenzuoli F
Evid Based Complement Alternat Med; 2019; 2019():2509129. PubMed ID: 31558911
[TBL] [Abstract][Full Text] [Related]
18. Research progress in the management of vascular disease with cannabidiol: a review.
Guo Y; Wei R; Deng J; Guo W
J Cardiothorac Surg; 2024 Jan; 19(1):6. PubMed ID: 38172934
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological effects of cannabidiol by transient receptor potential channels.
Etemad L; Karimi G; Alavi MS; Roohbakhsh A
Life Sci; 2022 Jul; 300():120582. PubMed ID: 35483477
[TBL] [Abstract][Full Text] [Related]
20. Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug.
Zuardi AW; Crippa JA; Hallak JE; Moreira FA; Guimarães FS
Braz J Med Biol Res; 2006 Apr; 39(4):421-9. PubMed ID: 16612464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
